In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity

Eur Urol. 2023 Apr;83(4):377-378. doi: 10.1016/j.eururo.2022.12.009. Epub 2023 Jan 7.

Authors

Gabriel E Molina¹, Ben Schwartz¹, Sandy Srinivas², Sumit Shah², Lisa C Zaba³

Affiliations

¹ Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.
² Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: lisa.zaba@stanford.edu.

PMID: 36623949
DOI: 10.1016/j.eururo.2022.12.009

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Carcinoma, Transitional Cell*
Humans
Immune Checkpoint Inhibitors
Urinary Bladder Neoplasms*

Substances

enfortumab vedotin
Immune Checkpoint Inhibitors
Antibodies, Monoclonal